FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Sarepta Reports Positive Data on Duchenne Gene Therapy

[ Price : $8.95]

Sarepta Therapeutics announces that its gene therapy Elevidys significantly slowed disease progression over three years in ambulat...

Advocacy Push Precedes FDA Meeting on Stalled Gene Therapy

[ Price : $8.95]

AMT-130 is a gene therapy designed to lower levels of the mutant huntingtin protein believed to drive Huntingtons disease progress...

Symposium on Clinical Trials, Bioequivalence and Pharmacovigilance

[ Price : $8.95]

U.S., U.K. and Canadian drug regulators announce a joint international symposium to discuss evolving regulatory expectations for c...

Former CytoDyn CEO Sentenced to Prison

[ Price : $8.95]

A federal judge sentences former CytoDyn chief executive Nader Pourhassan to 30 months in prison for misleading investors about th...

FDA Cites Pine Pharma Over Sterility, Quality Control

[ Price : $8.95]

FDA cites Pine Pharmaceuticals for multiple quality and sterility violations following a 10-day inspection of the companys drug ou...

FDA Reports Gains in Drug Inspection Program

[ Price : $8.95]

FDA says it continued to improve the speed and consistency of drug manufacturing oversight in fiscal year 2024, citing strong perf...

Testing Deficiencies Cited at Asahi Kasei Finechem API Plant

[ Price : $8.95]

FDA cites Asahi Kasei Finechem Co. for significant quality control deficiencies following a November inspection of the companys ac...

FDA Highlights Expedited Pathways in Drug Approval Report

[ Price : $8.95]

FDAs annual report on drug approvals says the majority of novel drugs approved in 2025 moved through accelerated regulatory pathwa...

Advocacy Groups Press Congress on Biosimilar Legislation

[ Price : $8.95]

Advocacy groups urge Congress to advance legislation that would eliminate the statutory distinction between biosimilars and so-cal...

Sanofi Reports Positive Data for Atopic Dermatitis Drug

[ Price : $8.95]

Sanofi says its experimental antibody amlitelimab showed consistent efficacy and a favorable safety profile across multiple late-s...